Antiandrogens in the Treatment of Prostate Cancer

  • Fritz H. Schröder
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Endocrine management of human prostatic carcinoma remains a controversial issue because of a number of unanswered questions. Such questions are: is there an optimal endocrine treatment? What is the best time to start endocrine treatment? Is it advantageous for our patients to exclude not only testicular but also adrenal androgens (total androgen suppression)? Does endocrine treatment prolong life? What is the best way to achieve proper palliation of long duration?


Advanced Prostatic Cancer Plasma Testosterone Adrenal Androgen Cyproterone Acetate Ventral Prostate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Knuth UA, Hano R, Nieschlag E: Effect of Flutamide or Cyproterone Acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1984 (59):963–969PubMedCrossRefGoogle Scholar
  2. 2.
    Carlström K, Pousette A, Stege R: Basal and ACTH-stimulated adrenal steroids in prostatic cancer patients during treatment with LH-RH analogue and Flutamide. Urol Res 1989 (17–5) Abstract 52:339Google Scholar
  3. 3.
    Schröder FH: Antiandrogenic substances in the management of prostatic cancer. In: Beck et al (eds) Recent Results in Cancer Research 118. Hormone-Related Malignant Tumors. Springer-Verlag, Berlin 1990 (in press)Google Scholar
  4. 4.
    Jacobi GH, Neumann F: The case for Cyproterone acetate. Bailliere’s Clin Oncol 1988 (2–3):571–580Google Scholar
  5. 5.
    Furr BJA: The case for pure antiandrogens. Bailliere’s Clin Oncol 1988 (2–3):581–590Google Scholar
  6. 6.
    Neri RO, Florance K, Koziol P, Cleave S van: A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4 ‘-Nitro3’-Trifluoromethylisobutyranilide). Endocrinol 1972 (91):427–37CrossRefGoogle Scholar
  7. 7.
    Neumann F, Habenicht UF, Schacher A: Antiandrogens and target cell response — different in vivo effects of cyproterone acetate, flutamide and cyproterone. In: McKerns W, Aakvaag A, Hansson V (eds) Regulation of Target Cell Responsiveness 2. Plenum Press, New York 1984 pp 489–527Google Scholar
  8. 8.
    DeKemion JB, Murphy GP, Priore R, Investigators of National Prostatic Cancer Project: Comparison of Flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology 1988 (21–4):312–317CrossRefGoogle Scholar
  9. 9.
    Lundgren R: Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 1988 (59)156–158Google Scholar
  10. 10.
    MacFarlane JR, Tolley DA: Flutamide therapy for advanced prostatic cancer: a phase II study. Br J Urol 1985 (57):172–174PubMedCrossRefGoogle Scholar
  11. 11.
    Ojasoo T: Nilutamide. Drugs of the Future 1987 (12–8):763–770Google Scholar
  12. 12.
    Brinkmann AO, Lindh LM, Breedveld DI, Mulder E, Molen HJ van der: Cyproterone Acetate prevents translocation of the androgen receptor in the rat prostate. Mol Cell Endocrinol 1983 (32):117–129PubMedCrossRefGoogle Scholar
  13. 13.
    Gallee MPW, Steenbrugge GJ van, Kate FJW ten, Schröder FH, Kwast ThH van der: Determination of the proliferative fraction of a transplantable hormone dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. JNCI 1987 (79):1333PubMedGoogle Scholar
  14. 14.
    Lund F, Rasmussen F: Flutamide versus Stilbestrol in the management of advanced prostatic cancer. Br J Urol 1988 (61):140–142.PubMedCrossRefGoogle Scholar
  15. 15.
    Radlmaier A, Bormacher K, Neumann F: Hot flushes: mechanism and prevention. In: Schröder FH (ed) EORTC Genitourinary Group Monograph 8: Treatment of Prostatic Cancer: Facts and Controversies. Alan R Liss, New York 1990 (in press)Google Scholar
  16. 16.
    Eaton AC, McGuire N: Cyproterone Acetate in treatment of post-orchidectomy hot flushes. Double blind cross over trial. The Lancet 1983 (8363):1336–1337CrossRefGoogle Scholar
  17. 17.
    Pavone-Macaluso M, Voogt HJ de, Viggiano G, Barasob B, Lardennoi B, Pauw M de, Sylvester R and members of the EORTC GU Group: Comparison of Diethylstilbestrol and Cyproterone acetate and Medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the EORTC Urobgical Group. J Urol 1986 (136):624–631PubMedGoogle Scholar
  18. 18.
    Varenhorst E: Metabolic changes during endocrine treatment in carcinoma of the prostate. A prospective study in man with special reference to cardiovascular complications during treatment with estrogens, or Cyproterone acetate or after orchiectomy. Thesis, Linköping University, 1980Google Scholar
  19. 19.
    Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R: Treatment of advanced prostatic cancer with parenteral Cyproterone acetate. A phase III randomized trial. Br J Urol 1980 (52):208–215PubMedCrossRefGoogle Scholar
  20. 20.
    Voogt HJ de, Smith PH, Pavone-Macaluso M et al: Cardiovascular side effects of Diethylstilbestrol, Cyproterone acetate, Medroxyprogesterone acetate and Estramustine phosphate used for the treatment of advanced prostatic cancer: results from EORTC trials 30761 and 30762. J Urol 1986 (135):303–307PubMedGoogle Scholar
  21. 21.
    Irwin RJ, Prout GJ, Jr.: A new antiprostatic agent for treatment of prostatic carcinoma. Surgical Forum 1973 (24):536–538PubMedGoogle Scholar
  22. 22.
    Stoliar B, Albert DJ: SCH 13521 in the treatment of advanced carcinoma of the prostate. J Urol 1974 (111):803–807PubMedGoogle Scholar
  23. 23.
    Prout GR, Irwin RJ, Kliman B, Daly JJ, MacLaughin RA, Griffin PP: Prostatic cancer and SCH 13421. II Histological and pituitary gonadal axis. J Urol 1975 (113):834–840PubMedGoogle Scholar
  24. 24.
    Jacobo E, Schmidt JD, Weinstein SH, Flocks RH: Comparison of Flutamide (Sch 13521) and Diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976 (8):231–233PubMedCrossRefGoogle Scholar
  25. 25.
    Airhart RA, Barnett TF, Sullivan JW, Levie RL, Schlegel JU: Flutamide therapy for carcinoma of the prostate. South Med J 1978 (71):798–801PubMedCrossRefGoogle Scholar
  26. 26.
    Narayana AS, Loaning SA, Culp DA: Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 1981 (53):152–153PubMedCrossRefGoogle Scholar
  27. 27.
    Sogani PC, Vagaiwala MR, Whitmore WF: Experience with Flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984 (54):774–750CrossRefGoogle Scholar
  28. 28.
    Neri RO, Kassem N: Biological and clinical properties of antiandrogens. In Bresciani F et al (eds) Progress in Cancer Research and Therapy 31. Raven Press, New York 1984 pp 507–518Google Scholar
  29. 29.
    Bosch R, Schröder FH: Radical prostatectomy and adjuvant endocrine treatment: a review. In: Schröder FH (ed) EORTC Genitourinary Group Monograph 8: Treatment of Prostatic Cancer: Facts and Controversies. Alan R Liss, New York 1990 (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Fritz H. Schröder
    • 1
  1. 1.Department of UrologyErasmus University and Academic HospitalDR RotterdamThe Netherlands

Personalised recommendations